Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes

被引：89

作者：

Valent, Peter ^{[1
,2
]}

Klion, Amy D. ^{[3
]}

Roufosse, Florence ^{[4
]}

Simon, Dagmar ^{[5
]}

Metzgeroth, Georgia ^{[6
]}

Leiferman, Kristin M. ^{[7
]}

Schwaab, Juliana ^{[6
]}

Butterfield, Joseph H. ^{[8
]}

Sperr, Wolfgang R. ^{[1
,2
]}

Sotlar, Karl ^{[9
]}

Vandenberghe, Peter ^{[10
,11
]}

Hoermann, Gregor ^{[12
]}

Haferlach, Torsten ^{[12
]}

Moriggl, Richard ^{[13
]}

George, Tracy, I ^{[14
]}

Akin, Cem ^{[15
]}

Bochner, Bruce S. ^{[16
]}

Gotlib, Jason ^{[17
]}

Reiter, Andreas ^{[6
]}

Horny, Hans-Peter ^{[18
]}

Arock, Michel ^{[19
]}

Simon, Hans-Uwe ^{[20
,21
]}

Gleich, Gerald J. ^{[7
,22
]}

机构：

[1] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

[2] Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

[3] NIH NIAID, Human Eosinophil Sect, Lab Parasit Dis, Bethesda, MD USA

[4] Univ Libre Bruxelles, Erasme Hosp, Dept Internal Med, Brussels, Belgium

[5] Univ Bern, Bern Univ Hosp, Dept Dermatol, Inselspital, Bern, Switzerland

[6] Univ Hosp Mannheim Heidelberg Univ, Dept Hematol & Oncol, Mannheim, Germany

[7] Univ Utah Hlth, Dept Dermatol, Salt Lake City, UT USA

[8] Mayo Clin, Div Allerg Dis, Rochester, MN USA

[9] Paracelsus Med Univ, Univ Hosp Salzburg, Inst Pathol, Salzburg, Austria

[10] Univ Hosp Leuven, Div Hematol, Leuven, Belgium

[11] Katholieke Univ Leuven, Dept Human Genet, Leuven, Belgium

[12] MLL Munich Leukemia Lab, Munich, Germany

[13] Univ Vet Med, Inst Anim Breeding & Genet, Vienna, Austria

[14] Univ Utah, Dept Pathol, Salt Lake City, UT USA

[15] Univ Michigan, Div Allergy & Clin Immunol, Ann Arbor, MI 48109 USA

[16] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA

[17] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA

[18] Ludwig Maximilian Univ Munich LMU, Inst Pathol, Munich, Germany

[19] Pierre & Marie Curie Univ UPMC, Pitie Salpetriere Hosp, Dept Hematol Biol, Paris, France

[20] Univ Bern, Inst Pharmacol, Bern, Switzerland

[21] Brandenburg Med Sch, Inst Biochem, Neuruppin, Germany

[22] Univ Utah Hlth, Dept Med, Salt Lake City, UT USA

来源：

ALLERGY | 2023年 / 78卷 / 01期

基金：

奥地利科学基金会; 瑞士国家科学基金会;

关键词：

classification; diagnostic criteria; eosinophilic leukemia; hypereosinophilic syndrome; personalized medicine; HYPEREOSINOPHILIC SYNDROME; IMATINIB MESYLATE; INTERLEUKIN-5; HEALTH; CYTOKINES; RESPONSES; FEATURES; DISEASES; RECEPTOR; VARIANT;

D O I：

10.1111/all.15544

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Eosinophilia and eosinophil activation are recurrent features in various reactive states and certain hematologic malignancies. In patients with hypereosinophilia (HE), HE-induced organ damage is often encountered and may lead to the diagnosis of a hypereosinophilic syndrome (HES). A number of known mechanisms and etiologies contribute to the development of HE and HES. Based on these etiologies and the origin of eosinophils, HE and HES are divided into primary forms where eosinophils are clonal cells, reactive forms where an underlying reactive or neoplastic condition is detected and eosinophils are considered to be "non-clonal" cells, and idiopathic HE and HES in which neither a clonal nor a reactive underlying pathology is detected. Since 2012, this classification and the related criteria have been widely accepted and regarded as standard. However, during the past few years, new developments in the field and an increasing number of markers and targets have created a need to update these criteria and the classification of HE and HES. To address this challenge, a Working Conference on eosinophil disorders was organized in 2021. In this conference, a panel of experts representing the relevant fields, including allergy, dermatology, hematology, immunology, laboratory medicine, and pathology, met and discussed new markers and concepts as well as refinements in definitions, criteria and classifications of HE and HES. The outcomes of this conference are presented in this article and should assist in the diagnosis and management of patients with HE and HES in daily practice and in the preparation and conduct of clinical trials.

引用

页码：47 / 59

页数：13

共 72 条

[1] Spectrum of Eosinophilic End-Organ Manifestations [J].